Penile Cancer

A punch biopsy confirms the diagnosis
A punch biopsy confirms the diagnosis

Table of Contents

  1. Overview
  2. Anatomy of the Penis
  3. Types of Penile Cancer
  4. Epidemiology
  5. Risk Factors
  6. Staging
  7. Diagnosis
  8. Treatment
  9. Complications
  10. Prognosis
  11. Prevention
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. Overview

Penile cancer is a malignancy that develops in the tissues of the penis. It is rare in the United States — about 2,260 new cases and about 450 deaths are expected in 2026, according to American Cancer Society estimates — but it carries a devastating physical and psychological burden because of where it occurs. Many men delay seeking evaluation out of embarrassment or fear, and that delay is genuinely dangerous. When penile cancer is found early, it is curable. Found late, it is not. That single fact is the most important thing on this page.

A sore, lump, thickening or colour change on the penis that has not healed is the main early sign of penile cancer. The skin of the penis does not routinely develop persistent lesions that do not resolve on their own, and only a biopsy tells cancer apart from harmless conditions that look similar. The 2023 European Association of Urology–American Society of Clinical Oncology guideline states that the disease can be cured in most cases without lymph node involvement.

About 95% of penile cancers are squamous cell carcinomas (SCC) — cancers that arise from the skin-like lining cells that cover the external surface and inner foreskin. There are two distinct biological pathways to penile SCC, one involving the human papillomavirus (HPV) and one involving chronic inflammation from a non-retractable foreskin (phimosis). Understanding which pathway applies matters for prognosis and, increasingly, treatment.

Penile cancer is far more common in parts of Africa, Asia, and South America where neonatal circumcision is uncommon and where it can account for up to 10% of all male cancers. In the United States and Western Europe it is uncommon but not vanishingly rare, and it is not a disease that only strikes older men — though most cases occur in men in their 60s and 70s.

This page uses honest language and real numbers. Some of what follows is difficult to read.

2. Anatomy of the Penis

Understanding where penile cancer can arise requires a brief map of the anatomy, because the location of the tumor influences treatment options, surgical planning, and outlook.

The penis has several distinct regions. The glans penis is the rounded distal tip — the most sensitive part, and in uncircumcised men it is covered by the foreskin (prepuce), a retractable fold of skin. Between the glans and the shaft of the penis runs a groove called the coronal sulcus. The shaft makes up the long body of the penis. Inside, two cylindrical structures called the corpora cavernosa (one on each side) fill with blood during erection; below them runs the corpus spongiosum, which surrounds the urethra (the tube carrying urine and semen).

These internal structures matter enormously for staging and surgery. Invasion into the corpus spongiosum indicates a more advanced tumor (T2). Invasion into the corpora cavernosa means the cancer has reached even deeper structures (T3). These distinctions determine whether organ-sparing surgery is possible or whether a partial or total penectomy is required.

Where penile cancers arise most often:

Lymphatic drainage follows a predictable path: superficial inguinal lymph nodes (in the groin) → deep inguinal nodes → pelvic lymph nodes (external iliac). This chain is critically important because penile cancer spreads primarily through the lymphatic system, and the status of the inguinal lymph nodes is the single most important factor predicting whether a man can be cured. Unlike some other cancers, "skip metastases" — where cancer jumps directly to deep nodes without first passing through superficial ones — are uncommon in penile cancer.

3. Types of Penile Cancer

The vast majority of penile cancers — about 95% — are squamous cell carcinomas (SCC), arising from the flat, skin-like cells on the surface of the penis. Within SCC there are several distinct subtypes that differ in their biology and prognosis:

Human papillomavirus-related pathway (approximately 40–50% of cases): human papillomavirus types 16 and 18 integrate into the DNA of penile epithelial cells and drive uncontrolled growth through a well-understood mechanism — the virus's E6 and E7 proteins deactivate the tumor-suppressor proteins p53 and Rb. The result is a type of pre-cancer called penile intraepithelial neoplasia (PeIN) — sometimes called Bowen's disease when on the shaft, or erythroplasia of Queyrat when on the glans. The human papillomavirus-related tumors tend to be warty or basaloid in histological appearance and may arise in somewhat younger men. Some evidence suggests human papillomavirus-positive tumors have a marginally better prognosis than human papillomavirus-negative ones, a question two 2025 meta-analyses have since examined (next paragraph).

Human papillomavirus status and outlook: A 2025 meta-analysis of 34 studies with 3,944 patients (Mustasam 2025) found that tumours positive for p16 (a marker of human papillomavirus-driven cancer) were linked to better overall survival (hazard ratio 0.54) and better disease-specific survival (hazard ratio 0.34). Tumours carrying human papillomavirus DNA had better disease-specific survival (hazard ratio 0.46) but not better overall survival. A second 2025 review (Vandermaesen 2025) pooled 23 studies with 5,291 men, of whom 36.8% had human papillomavirus-associated disease, and found the same pattern; all the studies it included were retrospective.

Non-HPV / chronic inflammation pathway (approximately 50–60% of cases): Phimosis — the inability to retract the foreskin — traps smegma (a mix of shed skin cells and secretions) beneath the prepuce. Over years, the resulting chronic inflammation and repeated minor trauma drive keratinocyte DNA damage and eventually keratinizing, differentiated SCC. This pathway is more common in older men and in populations where neonatal circumcision is less practiced. Lichen sclerosus (a chronic scarring condition of the foreskin and glans) is closely linked to this pathway.

Other, rarer types of penile cancer include:

4. Epidemiology

In the United States, about 2,260 men are expected to be diagnosed with penile cancer in 2026, and about 450 to die from it (American Cancer Society 2026 estimates). These are small numbers by cancer standards — penile cancer accounts for less than 1% of all male cancers in the US — but "rare" is cold comfort to the man facing it and his family.

The global picture is very different. In parts of Uganda, Brazil, and India, penile cancer accounts for up to 10% of all male cancers. Across sub-Saharan Africa and Southeast Asia, age-standardized incidence rates can be ten times higher than those in the United States. The dominant explanation is the combination of lower circumcision rates, higher human papillomavirus prevalence, and limited access to penile hygiene and healthcare.

Worldwide there are about 35,000 new penile cancer cases each year, and high-risk human papillomavirus infection is thought to be present in about 50% of cases (Chahoud 2021). The 2023 European Association of Urology–American Society of Clinical Oncology guideline states that the global incidence is increasing, names human papillomavirus as the main risk factor, and calls for pathology reports to include an assessment of human papillomavirus status.

In the United States, penile cancer is most common in men in their 60s and 70s. It is uncommon before age 40, though it can occur in younger men, particularly in the human papillomavirus-driven pathway. Rates are modestly higher in Black and Hispanic men in the US compared to non-Hispanic white men — a difference likely reflecting circumcision patterns and socioeconomic access to healthcare rather than intrinsic biology.

Circumcision and risk: Neonatal circumcision reduces the lifetime risk of penile cancer by roughly three-fold. A 2011 pooled analysis describes this effect as one that "could be mediated partly through an effect on phimosis" (Larke 2011), and a 2001 Los Angeles case-control study as "mediated in large part by phimosis" (Tsen 2001, PubMed PMID: 11405332); the reduction measured applies to invasive cancer, with little evidence for in situ cancer (see Phimosis). Circumcision in adulthood has not been shown to protect: a 2011 pooled analysis (Larke 2011) found a strong protective effect of childhood or adolescent circumcision on invasive penile cancer (odds ratio 0.33; 3 studies), but some evidence that circumcision in adulthood was linked to an increased risk (odds ratio 2.71; 95% CI 0.93–7.94; 3 studies). In two studies, the protection from childhood circumcision no longer held when the analysis was limited to boys with no history of phimosis, which the authors suggest means the effect works partly through phimosis. This is not an argument for universal circumcision — that is a personal and cultural decision — but it is a fact that the epidemiology makes impossible to ignore.

Human immunodeficiency virus (HIV) and immunosuppression increase the risk of penile cancer, most likely by impairing immune control of human papillomavirus infection. Men with human immunodeficiency virus have higher rates of penile PeIN and invasive cancer.

5. Risk Factors

Several well-established risk factors increase a man's chance of developing penile cancer. Knowing them does not mean any of this is a man's fault — most men with these exposures never develop the disease. But understanding the risks helps with screening awareness and prevention.

It is worth stating plainly: most men with penile cancer did not do anything "wrong." Phimosis is not a personal failing. Human papillomavirus infection is nearly universal among sexually active people. Smoking is an addiction. The risk factors above are tools for prevention and early detection, not a list of things to feel guilty about.

6. Staging

Penile cancer is staged using the AJCC 8th Edition (2017) system, which classifies the primary tumor (T), lymph node involvement (N) and distant spread (M). Stage at diagnosis — particularly whether cancer has spread to the inguinal lymph nodes — is the most important determinant of whether a man can be cured.

Primary Tumor (T)

Regional Lymph Nodes (N)

The AJCC system also has an M category: M0 means no distant spread, M1 means distant spread, and any M1 cancer is stage IV (National Cancer Institute PDQ). When distant spread does occur, the lung, liver, and bone are most common.

A critical clinical point: approximately 25% of men with clinically negative lymph nodes (cN0) on examination actually have occult micrometastases in the inguinal nodes that are too small to feel or see on imaging. This is why modern guidelines (EAU, NCCN) require pathological lymph node staging — not just clinical examination — for T1b and above. Treating a man as node-negative based on physical exam alone, when he actually has microscopic node disease, is one of the most important avoidable mistakes in penile cancer management.

7. Diagnosis

The diagnosis of penile cancer begins with an examination of the lesion — which many men delay for months or even years out of embarrassment. A lesion, sore, thickening, or discoloration on the penis that has not resolved in 3–4 weeks is the usual reason for that examination, and the first step is a small office biopsy under local anesthesia (below).

Biopsy of the Primary Lesion

A tissue biopsy is essential before any treatment can be planned. Treatment is not planned on visual appearance alone — several benign conditions can look similar. A punch biopsy (a small circular blade removes a core of tissue) or incisional biopsy (a small wedge of tissue) is performed under local anesthesia in an office or minor-procedure setting. The sample goes to a pathologist who determines: is it cancer? what subtype? what grade? is there lymphovascular invasion? These answers directly drive every treatment decision that follows.

Imaging

Lymph Node Staging

This is the most consequential part of the work-up, and it is where penile cancer management has become most sophisticated in recent years.

In centers without DSLNB expertise, modified inguinal lymph node dissection is the alternative for staging high-risk cN0 patients.

The 2023 European Association of Urology–American Society of Clinical Oncology guideline recommends surgical lymph node staging with sentinel node biopsy for men with a high-risk tumour (pT1b or higher) whose groin nodes feel normal (cN0). The guideline also notes that, because there are few controlled trials and large series, its levels of evidence and grades of recommendation are low compared with those for more common diseases.

8. Treatment

Treatment of penile cancer has two parallel tracks that must both be addressed: the primary tumor on the penis, and the inguinal (groin) lymph nodes. Both require attention. Treating the penile tumor while ignoring the nodes — or vice versa — leaves a man undertreated.

Treatment of the Primary Tumor

Organ-sparing approaches are strongly preferred when they can achieve adequate margins. Modern evidence shows that with appropriate patient selection, organ-sparing surgery gives comparable cancer control to more radical penectomy, with dramatically better quality of life. The preference for organ preservation is embedded in both the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) guidelines.

Inguinal Lymph Node Management

The management of the inguinal lymph nodes is the most critical part of penile cancer treatment and the area where errors are most likely to cost lives. The decision tree depends on what the nodes feel like (clinical N status) and the pathological T stage.

Systemic (Chemotherapy and Immunotherapy) Treatment

Systemic treatment plays a role in locally advanced and metastatic penile cancer, though it is not as well-developed as in some other solid tumors. Penile SCC is treated similarly to other squamous cell carcinomas of the head/neck and cervix, with regimens borrowed from those settings.

9. Complications

The complications of penile cancer come from both the disease itself and from its treatment. Understanding them in advance helps men and their families prepare, and helps ensure that supportive care is not treated as an afterthought.

Complications from Surgery

Complications from Radiotherapy

Psychological Impact

The psychological burden of penile cancer — and especially of partial or total penectomy — is profound. Men may experience depression, anxiety, grief over loss of sexual function, altered body image, relationship difficulties, and social withdrawal. These are not minor side effects; for many men they are among the most significant aspects of living with or after penile cancer. Psychiatrists, psychologists, and sexual health counselors experienced in genitourinary oncology are essential team members. Partners and families are affected too and benefit from inclusion in support resources.

10. Prognosis

The outlook in penile cancer depends more than anything else on whether the cancer has spread to the inguinal lymph nodes, and if so, how extensively. Stage at diagnosis is the dominant factor determining whether a man can be cured.

The American Cancer Society, using SEER data for men diagnosed between 2015 and 2021, reports five-year relative survival of 79% for localized cancer, 57% for regional spread, 10% for distant spread and 65% for all stages combined. The 2014 European Association of Urology guideline summary states that approximately 80% of penile cancer patients of all stages can be cured.

The number of positive inguinal lymph nodes is the strongest single predictor of outcome. Men with 0 positive nodes after adequate staging have an excellent chance of cure. Men with 3 or more positive nodes, or with extranodal extension, have a much higher risk of pelvic node involvement and distant recurrence.

These statistics describe groups. They cannot predict what will happen to any individual man. Men do better than the statistics predict, and some do worse. What the statistics tell us with certainty is this: early diagnosis saves lives. The difference between the prognosis at stage I and stage III is stark, and that gap is determined almost entirely by how quickly a man sought evaluation and whether his doctors staged his nodes correctly.

11. Prevention

Penile cancer is, to a significant degree, a preventable disease. Several well-established interventions meaningfully reduce risk.

Back to Table of Contents

Key Research Papers

  1. Leijte JAP, Kroon BK, Valdés Olmos RA, et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol. 2007;52(1):170–177. — PubMed PMID: 17316967 · doi:10.1016/j.eururo.2007.01.107
  2. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–3857. — PubMed PMID: 20625118 · doi:10.1200/JCO.2010.29.5477
  3. Hakenberg OW, Compérat EM, Minhas S, et al. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–150. — PubMed PMID: 25457021 · doi:10.1016/j.eururo.2014.10.017
  4. Crook JM, Haie-Meder C, Demanes DJ, et al. American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy. 2013;12(3):191–198. — PubMed PMID: 23453681 · doi:10.1016/j.brachy.2013.01.167
  5. Baumgarten AS, Chipollini J, Yan S, et al. Penile sparing surgery for penile cancer: a multicenter international retrospective cohort. J Urol. 2018;199(5):1233–1237. — PubMed PMID: 29132984 · doi:10.1016/j.juro.2017.10.045
  6. Djajadiningrat RS, Graafland NM, van Werkhoven E, et al. Contemporary management of regional nodes in penile cancer — improvement of survival? J Urol. 2014;191(1):68–73. — PubMed PMID: 23917166 · doi:10.1016/j.juro.2013.07.088
  7. Chahoud J, Kohli M, Spiess PE. Management of advanced penile cancer. Mayo Clin Proc. 2021;96(3):720–732. — PubMed PMID: 33308870 · doi:10.1016/j.mayocp.2020.06.031
  8. Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 2005;116(4):606–616. — PubMed PMID: 15825185 · doi:10.1002/ijc.21009
  9. Peak T, Zemp L, Spiess PE. Will dynamic sentinel lymph node biopsy surpass inguinal lymph node dissection in high-risk node-negative penile cancer? Eur Urol Oncol. 2022;5(6):712–713. — PubMed PMID: 36336613 · doi:10.1016/j.euo.2022.10.005
  10. Arya M, Kalsi J, Kelly J, Muneer A. Malignant and premalignant lesions of the penis. BMJ. 2013;346:f1149. — PubMed PMID: 23468288 · doi:10.1136/bmj.f1149
  11. Albersen M, Parnham A, Joniau S, et al. Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma. Urol Oncol. 2018;36(4):141.e1–141.e7. — PubMed PMID: 28882673 · doi:10.1016/j.urolonc.2017.07.025
  12. Brouwer OR, Albersen M, Parnham A, et al. European Association of Urology–American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update. Eur Urol. 2023;83(6):548–560. — PubMed PMID: 36906413 · doi:10.1016/j.eururo.2023.02.027
  13. El Zarif T, Nassar AH, Pond GR, et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023;115(12):1605–1615. — PubMed PMID: 37563779 · doi:10.1093/jnci/djad155
  14. Cotait Maluf F, Trindade K, Preto D, et al. Pembrolizumab plus platinum-based chemotherapy for patients with advanced penile cancer: the nonrandomized HERCULES (LACOG 0218) clinical trial. JAMA Oncol. 2025;11(11):1314–1320. — PubMed PMID: 40965911 · doi:10.1001/jamaoncol.2025.3266
  15. Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control. 2011;22(8):1097–1110. — PubMed PMID: 21695385 · doi:10.1007/s10552-011-9785-9
  16. Mustasam A, Parza K, Ionescu F, et al. The prognostic role of HPV or p16INK4a status in penile squamous cell carcinoma: a meta-analysis. J Natl Compr Canc Netw. 2025;23(2). — PubMed PMID: 39752880 · doi:10.6004/jnccn.2024.7078
  17. Vandermaesen K, Elst L, Defraigne C, et al. The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis. Int J Impot Res. 2025;37(9):782–793. — PubMed PMID: 40770564 · doi:10.1038/s41443-025-01145-z
  18. Moreno G, Corbalán J, Peñaloza B, Pantoja T. Topical corticosteroids for treating phimosis in boys. Cochrane Database Syst Rev. 2014;2014(9):CD008973. — PubMed PMID: 25180668 · doi:10.1002/14651858.CD008973.pub2

PubMed Topic Searches

The links below run live searches on PubMed, the U.S. National Library of Medicine's database of biomedical literature. Results update as new studies are published.

  1. PubMed: Penile cancer sentinel lymph node biopsy inguinal
  2. PubMed: Penile squamous cell carcinoma HPV circumcision
  3. PubMed: Penile intraepithelial neoplasia PeIN treatment
  4. PubMed: Partial penectomy organ-sparing penile cancer
  5. PubMed: Neoadjuvant chemotherapy TIP metastatic penile cancer
  6. PubMed: Pembrolizumab immunotherapy penile cancer
  7. PubMed: Penile brachytherapy radiation therapy organ preservation
  8. PubMed: Lichen sclerosus penile cancer risk
  9. PubMed: Penile cancer inguinal lymph node dissection lymphedema
  10. PubMed: Phimosis penile cancer risk

Back to Table of Contents

14. Connections

Back to Table of Contents